Search Results - Yoon Sim Yap

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer by Jun Ma, Jack Junjie Chan, Ching Han Toh, Yoon-Sim Yap

    Published in npj Breast Cancer (2023-09-01)
    Get full text
    Article


  2. 2

    Classification of HER2-negative breast cancers by copy number alteration status reveals molecular differences associated with chromosome 17 gene aberrations by Jui Wan Loh, Abner Herbert Lim, Jason Yongsheng Chan, Yoon-Sim Yap

    Published in Therapeutic Advances in Medical Oncology (2023-10-01)
    Get full text
    Article


  3. 3

    Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial by Joanne Chiu, Fei Su, Mukta Joshi, Norikazu Masuda, Takashi Ishikawa, Tomoyuki Aruga, Juan Pablo Zarate, Naveen Babbar, O. Alejandro Balbin, Yoon-Sim Yap

    Published in BMC Medicine (2023-08-01)
    Get full text
    Article


  4. 4

    Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer by Ning-Yuan Lee, Melissa Hum, Sabna Zihara, Lanying Wang, Matthew K. Myint, Darren Wan-Teck Lim, Chee-Keong Toh, Anders Skanderup, Jens Samol, Min-Han Tan, Peter Ang, Soo-Chin Lee, Eng-Huat Tan, Gillianne G. Y. Lai, Daniel S. W. Tan, Yoon-Sim Yap, Ann S. G. Lee

    Published in Human Genomics (2023-07-01)
    Get full text
    Article


  5. 5

    Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer by Ning-Yuan Lee, Melissa Hum, Sabna Zihara, Lanying Wang, Matthew K. Myint, Darren Wan-Teck Lim, Chee-Keong Toh, Anders Skanderup, Jens Samol, Min-Han Tan, Peter Ang, Soo-Chin Lee, Eng-Huat Tan, Gillianne G. Y. Lai, Daniel S. W. Tan, Yoon-Sim Yap, Ann S. G. Lee

    Published in Human Genomics (2023-08-01)
    Get full text
    Article


  6. 6

    Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden by Guanhua Zhu, Yu A. Guo, Danliang Ho, Polly Poon, Zhong Wee Poh, Pui Mun Wong, Anna Gan, Mei Mei Chang, Dimitrios Kleftogiannis, Yi Ting Lau, Brenda Tay, Wan Jun Lim, Clarinda Chua, Tira J. Tan, Si-Lin Koo, Dawn Q. Chong, Yoon Sim Yap, Iain Tan, Sarah Ng, Anders J. Skanderup

    Published in Nature Communications (2021-04-01)
    Get full text
    Article


  7. 7

    Evaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting by Han Yi Lee, Vivianne Shih, Jack Junjie Chan, Shun Zi Liong, Ryan Shea Ying Cong Tan, Jun Ma, Bernard Ji Guang Chua, Joshua Zhi Chien Tan, Chuan Yaw Lee, Wei Ling Teo, Su-Ming Tan, Phyu Nitar, Yoon Sim Yap, Mabel Wong, Rebecca Dent, Fuh Yong Wong, Tira J Tan

    Published in Annals, Academy of Medicine, Singapore (2025-08-01)
    Get full text
    Article


  8. 8

    A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer by Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai, Naohito Yamamoto, Chi-Feng Chung, Yen-Shen Lu, Dwan-Ying Chang, Joohyuk Sohn, Gun Min Kim, Kyung-Hun Lee, Soo-Chin Lee, Tsutomu Iwasa, Hiroji Iwata, Kenichi Watanabe, Kyung Hae Jung, Yuko Tanabe, Seok Yun Kang, Hiroyuki Yasojima, Kenjiro Aogi, Eriko Tokunaga, Sung Hoon Sim, Yoon Sim Yap, Koji Matsumoto, Ling-Ming Tseng, Yoshiko Umeyama, Kazuki Sudo, Yuki Kojima, Tomomi Hata, Aya Kuchiba, Taro Shibata, Kenichi Nakamura, Yasuhiro Fujiwara, Kenji Tamura, Kan Yonemori

    Published in npj Breast Cancer (2024-08-01)
    Get full text
    Article


Search Tools: